Safe use of a once-a-week glucagon-like peptide-1 receptor agonist in a 16-year-old girl with type 2 diabetes when approved therapy options fail.
Louisa van den BoomTheresa StuecherJulia Katharina MaderPublished in: Clinical case reports (2021)
This case report demonstrates that using a non-approved long-acting GLP-1-RA (dulaglutide) in adolescents with T2D is possible and feasible under special circumstances when approved therapeutic options for the pediatric population fail to achieve adequate glycemic control.
Keyphrases
- glycemic control
- drug administration
- case report
- type diabetes
- young adults
- blood glucose
- rheumatoid arthritis
- physical activity
- weight loss
- clinical trial
- stem cells
- metabolic syndrome
- disease activity
- systemic lupus erythematosus
- ankylosing spondylitis
- bone marrow
- placebo controlled
- idiopathic pulmonary fibrosis
- double blind